Metabolic Phase 3 Readout Calendar
Industry-sponsored metabolic trials with primary completion in the next 12 months or last 12 months.
Data last updated November 12, 2026 · source: ClinicalTrials.gov
All areas OncologyImmunologyMetabolicCNSCardiovascularRespiratoryRare DiseaseInfectious DiseaseMusculoskeletalDermatologyOphthalmology
41
Next 6 months
70
Next 12 months
22
Results posted
300
Phase 3 Metabolic
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 metabolic trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
What metabolic trials are reading out soon?
The "upcoming" section shows industry-sponsored Phase 3 metabolic trials with primary completion ahead, soonest first, each graded by how credible that date is.
Which metabolic trials have already read out?
The "recently read out" section shows Phase 3 metabolic trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.
How are these readout dates sourced?
Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.
Where can I see readouts for other therapeutic areas?
The full cross-area calendar is on the main readout calendar; this page is the Metabolic slice of it.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Metabolic landscape →
Recently read out & awaiting topline — Metabolic
· 18Phase 3 metabolic trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk Asset: Orforglipron | Type 2 Diabetes +5 | Completed | Q1 2026 2026-03-16 | Completed · awaiting
Updated 7mo ago
| NCT05803421 |
| Novo Nordisk A/S | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Asset: Cagrilintide | Type 2 Diabetes | Completed | Q1 2026 2026-03-04 | Completed · awaiting
Updated 7mo ago
| NCT06221969 |
| CSPC Baike (Shandong) Biopharmaceu… | A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus Asset: TG103 | Type 2 Diabetes Mellitus | Completed | Q1 2026 2026-02-03 | Completed · awaiting
Updated 7mo ago
| NCT06235086 |
| CSPC Baike (Shandong) Biopharmaceu… | A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus Asset: TG103 | Type 2 Diabetes Mellitus | Completed | Q1 2026 2026-01-23 | Completed · awaiting
Updated 7mo ago
| NCT06258148 |
| Eli Lilly and Company | Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Asset: Retatrutide | Diabetes Type 2 | Completed | Q1 2026 2026-01-22 | Completed · awaiting
Updated 8mo ago
| NCT06354660 |
| Eli Lilly and Company | A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Asset: Tirzepatide | Overweight +1 | Completed | Q1 2026 2026-01-20 | Completed · awaiting
Updated 8mo ago
| NCT06047548 |
| Eli Lilly and Company | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Asset: Ixekizumab | Psoriasis +1 | Completed | Q1 2026 2026-01-08 | Completed · awaiting
Updated 10mo ago
| NCT06588283 |
| Bayer | A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema Asset: 8 mg aflibercept (BAY 86-5321) (High Dose) | Diabetic Macular Edema | Completed | Q4 2025 2025-12-29 | Completed · awaiting
Updated 7mo ago
| NCT06422507 |
| Rhythm Pharmaceuticals, Inc. | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway Asset: Setmelanotide | Obesity +1 | Completed | Q4 2025 2025-12-22 | Completed · awaiting
Updated 9mo ago
| NCT05093634 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight | Obesity +1 | Completed | Q4 2025 2025-12-12 | Completed · awaiting
Updated 7mo ago
| NCT06066528 |
| Novo Nordisk A/S | A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight Asset: Cagrilintide | Obesity | Completed | Q4 2025 2025-12-08 | Completed · awaiting
Updated 9mo ago
| NCT06131437 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease Asset: Survodutide | Obesity | Completed | Q4 2025 2025-12-03 | Completed · awaiting
Updated 11mo ago
| NCT06176365 |
| Boehringer Ingelheim | A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Obesity | Completed | Q4 2025 2025-12-02 | Completed · awaiting
Updated 8mo ago
| NCT06066515 |
| Vincentage Pharma Co., Ltd | A Research Study of VCT220 in Adult Chinese Participants With Obesity Asset: VCT220 | Obesity +1 | Completed | Q4 2025 2025-11-25 | Completed · awaiting
Updated 8mo ago
| NCT06939296 |
| Eli Lilly and Company | A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN) Asset: Orforglipron | Obesity +1 | Completed | Q4 2025 2025-11-21 | Completed · awaiting
Updated 11mo ago
| NCT06584916 |
| Novo Nordisk A/S | A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Asset: Cagrilintide | Type 2 Diabetes Mellitus | Completed | Q4 2025 2025-11-19 | Completed · awaiting
Updated 10mo ago
| NCT06065540 |
| Eli Lilly and Company | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Asset: Ixekizumab | Psoriatic Arthritis +1 | Completed | Q4 2025 2025-11-18 | Completed · awaiting
Updated 10mo ago
| NCT06588296 |
| Eli Lilly and Company | A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee Asset: Retatrutide | Obesity +2 | Completed | Q4 2025 2025-11-14 | Completed · awaiting
Updated 10mo ago
| NCT05931367 |
Upcoming metabolic readouts — next 12 months
· 70Industry Phase 3 metabolic trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight Asset: Tirzepatide | Type 1 Diabetes +2 | Active Not Recruiting | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 9mo ago
| NCT06914895 |
| Eli Lilly and Company | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight Asset: Tirzepatide | Type 1 Diabetes +2 | Active Not Recruiting | Q4 2026 2026-11 (est.) | Estimated · aging
Updated 9mo ago
| NCT06962280 |
| Eli Lilly and Company | A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight Asset: Orforglipron | OSA +1 | Completed | Q4 2026 2026-11 (est.) | Estimated · stale
Updated 13mo ago
| NCT06649045 |
| Vanda Pharmaceuticals | A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use Asset: Tradipitant | Nausea and Vomiting +1 | Recruiting | Q4 2026 2026-12-01 (est.) | Estimated · aging
Updated 7mo ago
| NCT07446439 |
| Guangdong Raynovent Biotech Co., Ltd | A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone Asset: RAY1225 | T2DM | Not Yet Recruiting | Q4 2026 2026-12-01 (est.) | Estimated · stale
Updated 15mo ago
| NCT07139535 |
Unlock 65 more metabolic readouts · plus filters on the full calendar
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.